Voyager Therapeutics (VYGR) Competitors $2.92 -0.08 (-2.51%) As of 02:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VYGR vs. NAGE, VIR, AVXL, NUVB, QURE, IMNM, AVBP, TRVI, PHAR, and DAWNShould you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include Niagen Bioscience (NAGE), Vir Biotechnology (VIR), Anavex Life Sciences (AVXL), Nuvation Bio (NUVB), uniQure (QURE), Immunome (IMNM), ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), Pharming Group (PHAR), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical products" industry. Voyager Therapeutics vs. Niagen Bioscience Vir Biotechnology Anavex Life Sciences Nuvation Bio uniQure Immunome ArriVent BioPharma Trevi Therapeutics Pharming Group Day One Biopharmaceuticals Voyager Therapeutics (NASDAQ:VYGR) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability. Which has preferable valuation and earnings, VYGR or NAGE? Voyager Therapeutics has higher earnings, but lower revenue than Niagen Bioscience. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVoyager Therapeutics$66.96M2.43$132.33M-$1.46-2.01Niagen Bioscience$107.93M7.26$13.39M$0.1758.53 Does the MarketBeat Community favor VYGR or NAGE? Voyager Therapeutics received 401 more outperform votes than Niagen Bioscience when rated by MarketBeat users. CompanyUnderperformOutperformVoyager TherapeuticsOutperform Votes40167.97% Underperform Votes18932.03% Niagen BioscienceN/AN/A Which has more volatility & risk, VYGR or NAGE? Voyager Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500. Does the media refer more to VYGR or NAGE? In the previous week, Voyager Therapeutics had 5 more articles in the media than Niagen Bioscience. MarketBeat recorded 6 mentions for Voyager Therapeutics and 1 mentions for Niagen Bioscience. Voyager Therapeutics' average media sentiment score of 0.74 beat Niagen Bioscience's score of 0.00 indicating that Voyager Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend VYGR or NAGE? Voyager Therapeutics currently has a consensus target price of $13.39, indicating a potential upside of 355.44%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Voyager Therapeutics is more favorable than Niagen Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Voyager Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Niagen Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is VYGR or NAGE more profitable? Voyager Therapeutics has a net margin of 15.80% compared to Niagen Bioscience's net margin of 0.00%. Voyager Therapeutics' return on equity of 8.33% beat Niagen Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Voyager Therapeutics15.80% 8.33% 6.15% Niagen Bioscience N/A N/A N/A Do insiders & institutionals believe in VYGR or NAGE? 48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 6.4% of Voyager Therapeutics shares are held by company insiders. Comparatively, 9.4% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryVoyager Therapeutics beats Niagen Bioscience on 12 of the 18 factors compared between the two stocks. Get Voyager Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYGR vs. The Competition Export to ExcelMetricVoyager TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$162.69M$2.91B$5.31B$8.28BDividend YieldN/A1.63%5.20%4.10%P/E Ratio4.1430.8726.7319.58Price / Sales2.43396.15387.44119.65Price / Cash1.41168.6838.2534.62Price / Book0.553.206.744.47Net Income$132.33M-$72.35M$3.23B$248.22M7 Day Performance-10.91%1.45%-0.05%-1.32%1 Month Performance-15.76%1.52%8.51%10.73%1 Year Performance-63.70%-25.72%18.25%8.40% Voyager Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYGRVoyager Therapeutics4.6574 of 5 stars$2.92-2.5%$13.39+359.3%-64.0%$161.30M$66.96M4.11100Gap DownNAGENiagen BioscienceN/A$9.39+4.9%N/AN/A$738.84M$99.60M55.24120News CoverageGap DownVIRVir Biotechnology2.9115 of 5 stars$5.30+4.1%$32.86+519.9%-59.5%$731.74M$14.30M-1.35580News CoveragePositive NewsAnalyst ForecastAnalyst RevisionGap DownAVXLAnavex Life Sciences3.8508 of 5 stars$8.55+3.6%$44.00+414.6%+70.4%$729.93MN/A-15.5540NUVBNuvation Bio3.6947 of 5 stars$2.15+2.6%$7.83+265.2%-31.6%$726.47M$7.87M-0.9960Positive NewsGap UpQUREuniQure2.9676 of 5 stars$13.15+2.8%$37.82+187.6%+202.2%$720.30M$27.12M-2.65500Options VolumeAnalyst RevisionIMNMImmunome2.6297 of 5 stars$7.94+6.4%$25.33+219.1%-41.3%$690.88M$9.04M-0.9840Positive NewsAnalyst UpgradeAVBPArriVent BioPharma0.9907 of 5 stars$19.99-0.8%$39.00+95.1%+3.7%$680.56MN/A-7.7840Analyst ForecastTRVITrevi Therapeutics3.4715 of 5 stars$6.70+1.5%$17.56+162.1%+127.5%$669.28MN/A-15.2320News CoveragePositive NewsAnalyst ForecastPHARPharming Group1.7822 of 5 stars$9.81-2.2%$30.00+206.0%+13.3%$667.04M$297.20M-37.71280Gap UpDAWNDay One Biopharmaceuticals2.7422 of 5 stars$6.58+2.0%$30.57+364.6%-57.1%$666.96M$161.92M-6.3960 Related Companies and Tools Related Companies Niagen Bioscience Alternatives Vir Biotechnology Alternatives Anavex Life Sciences Alternatives Nuvation Bio Alternatives uniQure Alternatives Immunome Alternatives ArriVent BioPharma Alternatives Trevi Therapeutics Alternatives Pharming Group Alternatives Day One Biopharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VYGR) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.